Dupilumab for the treatment of atopic dermatitis: Real-world data from the Czech Republic BIOREP registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10439956" target="_blank" >RIV/00064165:_____/22:10439956 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/22:43923005 RIV/00064203:_____/22:10439956 RIV/00216208:11110/22:10439956 RIV/00216208:11120/22:43923005 RIV/00216208:11140/22:10439956
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jw6L0xUGun" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=jw6L0xUGun</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/09546634.2022.2043545" target="_blank" >10.1080/09546634.2022.2043545</a>
Alternative languages
Result language
angličtina
Original language name
Dupilumab for the treatment of atopic dermatitis: Real-world data from the Czech Republic BIOREP registry
Original language description
BACKGROUND: Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited. OBJECTIVE: To analyze the effectiveness and safety of dupilumab. METHODS: This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD. RESULTS: A total of 360 patients were included. At 16 weeks, 66.6%, 34.1%, and 5.5% of patients achieved EASI75/90 and EASI100, respectively. Improvement continued with the time, and the proportion of patients with EASI75/90 and EASI100 increased to 89.5%, 55.6%, and 12.9% after one year of treatment and reached 95.8%, 60.4%, and 27.1% in the second year of therapy, respectively. A significant reduction was observed in the DLQI scores. The most common adverse events were infections in 5.8% of patients, followed by ocular complications in 2.5% of patients. Persistence rates were 98.2% at four months to 93.1% at month 24, and lack of effectiveness was the most common reason for discontinuation. CONCLUSION: This real-life study confirmed the effectiveness and safety of dupilumab in a real-life setting during the COVID-19 pandemic. Our study revealed a higher frequency of infections and a lower conjunctivitis frequency than other real-life studies and clinical trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Dermatological Treatment
ISSN
0954-6634
e-ISSN
1471-1753
Volume of the periodical
33
Issue of the periodical within the volume
5
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
2578-2586
UT code for WoS article
000758707700001
EID of the result in the Scopus database
2-s2.0-85125595616